Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS (Weanilevo)

University Hospital Center (CHU) Dijon Bourgogne

Status and phase: Terminated; Phase 3

Conditions: Acute Decompensated Heart Failure

Treatments: Drug: Levosimendan; Drug: Cernevit

Study type: Interventional

Funder types: Other

Identifiers

NCT04158674

ELLOUZE_ORION_2018

Details and patient eligibility

About

Extracorporeal life support (ECLS) is a circulatory cardio supplementation technique; it therefore makes it possible to compensate for a defective cardiac or cardio-respiratory function. ECLS nevertheless remains a temporary assistance technique pending a potential recovery of cardiac function, or it can be used to direct patients towards a heart transplant or long-term circulatory assistance (Left Ventricular Assist Device (LVAD) or Total Heart). In patients with complete or partial recovery of cardiac and circulatory function, ECLS withdrawal may be considered. Withdrawal from ECLS remains a delicate phase and the risk of failure is high. The mechanism of action of levosimendan, a drug that increases the contractility of the heart, suggests that it would improve the heart-vessel connection and reduce the rate of ECLS withdrawal failure. The effect of levosimendan is maximal 24 to 48 hours after the end of the infusion and has a prolonged period of action.

The objective is to evaluate the efficacy of levosimendan administration (0.2 µg/kg/min over 24 hours) - versus placebo - prior to ECLS removal on the rate of withdrawal failure in patients under ECLS.

Enrollment: 82 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• adult patient

• patient or person responsible for the patient has given written consent

• patient with acute circulatory heart failure under ECLS

• patient meeting criteria for ECLS withdrawal

  • ECLS flow rate at 1.0-1.5l/min and/or ECLS pump rpm ≤ 1500 rpm
  • LVEF > 20% in cardiac ultrasound and aortic ITV > 10 cm
  • VIS score ≤ 10
  • Arterial lactates ≤ 2 mmol/l
  • Right ventricular outflow tract shortening fraction > 30%
  • Basal diameter at the tricuspid telediastolic ring of the right ventricle < 35 mm
  • Fraction of inspired oxygen combined between ventilator and ECLS < 80%

• ECLS withdrawl scheduled within 48 hours

• Absence of an initial or progressive infectious episode (no planned introduction of antibiotic therapy within 48 hours prior to inclusion)

Exclusion criteria

• Patient with hepatic insufficiency: cytolysis at least 20 times normal

• Drug intoxication and attempted suicide

• Patient with a contraindication to the use of levosimendan:

  • hypersensitivity to the active substance or any of the excipients
  • severe hypotension and ventricular tachycardia
  • significant mechanical obstructions affecting ventricular filling and/or ejection
  • severe renal failure (creatinine clearance < 30 ml/min)
  • severe liver failure (TP<50%)
  • history of torsades de pointes

• Patient with a contraindication to the use of CERNEVIT®:

  • hypersensitivity to active substances, in particular to vitamin B1 or to one of the excipients or to soy protein products or to peanut protein products
  • hypervitaminosis to any vitamin contained in this formulation
  • severe hypercalcemia, hyper calciuria, tumour, bone metastasis, primary hyperparathyroidism, granulomatosis

• patient not affiliated to or not benefiting from national health insurance

• patient subject to legal protection (curatorship, guardianship)

• patient subject to limited judicial protection

• pregnant, parturient or breastfeeding woman

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

82 participants in 2 patient groups

Levosimendan

Experimental group

Treatment:

Drug: Levosimendan

Placebo

Sham Comparator group

Treatment:

Drug: Cernevit